Clinical evidence-based study on new-generation drug-eluting stent: everolimus-eluting stents (Xience V)

Abstract

Abstract: Percutaneous coronary intervention (PCI) has been a mainstay in the management of coronary artery disease since its introduction in the late 1970s. Bare-metal stents and, more recently, first-generation drug-eluting stents (DES), such as sirolimuseluting (Cypher) and paclitaxel-eluting stents (Taxus), have further improved results of percutaneous coronary intervention by improving early results and reducing the risk of restenosis. There are currently debates on the safety of these first-generation DES, given the potential for late stent thrombosis which is a first-generation drug-eluting stent of the largest security issue, especially after discontinuation of dual antiplatelet therapy. Next-generation DES such as everolimus-eluting stents (Xience V) holds the promise of superior antirestenosis efficacy as well as long-term safety. This review makes a presentation of the evidence-based clinical research according to everolimus-eluting stents (Xience V).

Key words: coronary artery disease, everolimus, percutaneous transluminal coronary angioplasty, stent

CLC Number:

R969
R543

GAO Wen-jun, LIU Wen-jie, KE Yong-sheng. Clinical evidence-based study on new-generation drug-eluting stent: everolimus-eluting stents (Xience V)[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(5): 591-595.

References

[1] Morice MC, Serruys PW, Sousa JE, et al.A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascul-arization[J]. N Engl J Med, 2002, 346(23): 1773-1780.
[2] Moses JW, LeonMB, Popma JJ, et al.Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery [J]. N Engl J Med, 2003, 349 (14): 1315-1323.
[3] Grube E, Silber S, Hauptmann KE, et al.TAXUS I: sixand twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions[J]. Circulation, 2003, 107(1): 38-42.
[4] Colombo A, Drzewiecki J, Banning A, et al.Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions[J]. Circulation, 2003, 108(7): 788-794.
[5] Stone GW, Ellis SG, Cox DA, et al.A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease[J]. N Engl J Med, 2004, 350(3): 221-231.
[6] Biondi-Zoccai GG, Agostoni P, Abbate A, et al.A simple hint to improve Robinson and Dickersin's highly sensitive PubMed search strategy for controlled clinical trials [J]. Int J Epidemiol, 2005, 34(1): 224-225.
[7] Biondi-Zoccai GG, LotrionteM, Agostoni P, et al.A systematic review and meta-analy sis on the hazards of discontinuing or not adhering to aspirin among 50279 patients at risk for coronary artery disease[J]. Eur Heart J, 2006, 27 (22): 2667-2674.
[8] Meredith I, Ormiston J, Whitbourn R, et al.First-in-human study of the endeavor zotarolimus-eluting phosphorylcholine- encapsulated stent system in de novo native coronary artery lesions:Endeavor I trial[J]. EuroIntervention, 2005, 1(5): 157-164.
[9] Fajadet J, Wijns W, Laarman GJ, et al. Randomized, double-blind, multi- center study of the Endeavor zotarolimus- eluting phosphorylcholine- encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR IItrial[J]. Circulation, 2006, 114(8): 798-806.
[10] Fajadet J, Wijns W, Laarman GJ, et al. Randomized, double-blind, multicenter study of the Endeavor zotarolimus- eluting phosphoryl- choline-encapsulated stent for treatment of native coronary artery lesions.Clinical and angiographic results of the ENDEAVOR II Trial[J]. Minerva Cardioangiol, 2007, 55(1): 1-18.
[11] Kandzari DE, Leon MB, Popma JJ, et al.Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial[J]. J Am Coll Cardiol, 2006, 48(12): 2440-2447.
[12] Leon MB. Endeavor clinical trial program[EB/OL]. Accessed 16 October 2007.URL:http://www.crtonline. org/flash. aspx ? 2007, PAGE ID=4728.
[13] Tanimoto S, Serruys PW, Thuesen L, et al.Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimus-eluting cobalt chromium coronary stent:Insights from the ABSORB and SPIRIT trials[J]. Catheter Cardiovasc Interv, 2007, 70(4): 515-523.
[14] Ortolani P, Marzocchi A, Marrozzini C, et al.Randomized comparative trial of a thin-strut bare metal cobaltchromium stent versus a sirolimus-eluting stent for coronary revascularization[J]. Catheter Cardiovasc Interv, 2007, 69 (6): 790-798.
[15] Xu YW, Wei YD, Tang K, et al. Multi-link Vision and MiniVision stent registry in Asian patients with coronary artery disease: a prospec- tive, multi-center study [J]. Chin Med J (Engl), 2007, 120(12): 1093-1096.
[16] Carter AJ, Brodeur A, Collingwood R, et al. Experimental efficacy of an everolimus eluting cobalt chromium stent [J]. Catheter Cardiovasc Interv, 2006, 68(1): 97-103.
[17] Waksman R, Pakala R, Baffour R, et al.Optimal dosing and duration of oral everolimus to inhibit in-stent neointimal growth in rabbit iliac arteries[J]. Cardiovasc Revasc Med, 2006, 7(3): 179-184.
[18] Verheye S, Martinet W, Kockx MM, et al.Selective clearance of macrophages in atherosclerotic plaques by autophagy[J]. J Am Coll Cardiol, 2007, 49(6): 706-715.
[19] Martinet W, Verheye S, De Meyer GR.Everolimus-induced mTOR inhibition selectively depletes macrophages in atherosclerotic plaques by autophagy [J]. Autophagy, 2007, 3(3): 241-244.
[20] Martinet W, Verheye S, De Meyer, GR.Selective depletion of macroph-ages in atherosclerotic plaques via macrophage- specific initiation of cell death[J]. Trends Cardiovasc Med, 2007, 17(2): 69-75.
[21] Serruys P, Ong A, Piek JJ, et al. A randomized comparison of a durable polymer everolimus-eluting stent with a bare metal coronary stent: The SPIRIT first trial[J]. EuroIntervention, 2005, 1(8): 58-65.
[22] Biondi-Zoccai GG, Chieffo A, Agostoni P, et al. Applying intravascular ultrasound to optimize the placement of coronary drug-eluting stents[J]. Minerva Cardioangiol, 2005, 53(3): 165-176.
[23] Agostoni P, Valgimigli M, Abbate A, et al.Is late luminal loss an accurate predictor of the clinical effectiveness of drug-eluting stents in the coronary arteries[J] ? Am J Cardiol, 2006, 97(5): 603-605.
[24] Tsuchida K, Garcia-Garcia HM, Ong AT, et al. Revisiting late loss and neointimal volumetric measurements in a drug-eluting stent trial:analysis from the SPIRIT FIRST trial[J]. Catheter Cardiovasc Interv, 2006, 67(2): 188- 197.
[25] Serruys P, Ruygrok P, Neuzner J, et al. A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coron-ary stent: the SPIRIT II trial[J]. EuroIntervention, 2006, 2(12): 286-294.